KR20190098982A - 트리아진트리온 유도체 및 뉴로트로핀 수용체 및 수용체 티로신 키나제의 조절제로서의 이의 용도 - Google Patents

트리아진트리온 유도체 및 뉴로트로핀 수용체 및 수용체 티로신 키나제의 조절제로서의 이의 용도 Download PDF

Info

Publication number
KR20190098982A
KR20190098982A KR1020197018642A KR20197018642A KR20190098982A KR 20190098982 A KR20190098982 A KR 20190098982A KR 1020197018642 A KR1020197018642 A KR 1020197018642A KR 20197018642 A KR20197018642 A KR 20197018642A KR 20190098982 A KR20190098982 A KR 20190098982A
Authority
KR
South Korea
Prior art keywords
compound
disease
alkyl
pharmaceutically acceptable
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197018642A
Other languages
English (en)
Korean (ko)
Inventor
군나르 노르드발
폰투스 포셀
요한 샌딘
Original Assignee
알제큐어 파마 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알제큐어 파마 에이비 filed Critical 알제큐어 파마 에이비
Publication of KR20190098982A publication Critical patent/KR20190098982A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197018642A 2016-12-21 2017-12-21 트리아진트리온 유도체 및 뉴로트로핀 수용체 및 수용체 티로신 키나제의 조절제로서의 이의 용도 Ceased KR20190098982A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1651706 2016-12-21
SE1651706-2 2016-12-21
PCT/GB2017/053868 WO2018115891A1 (en) 2016-12-21 2017-12-21 Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases

Publications (1)

Publication Number Publication Date
KR20190098982A true KR20190098982A (ko) 2019-08-23

Family

ID=60923799

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197018642A Ceased KR20190098982A (ko) 2016-12-21 2017-12-21 트리아진트리온 유도체 및 뉴로트로핀 수용체 및 수용체 티로신 키나제의 조절제로서의 이의 용도

Country Status (12)

Country Link
US (1) US20200113910A1 (cg-RX-API-DMAC7.html)
EP (1) EP3558320A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020502225A (cg-RX-API-DMAC7.html)
KR (1) KR20190098982A (cg-RX-API-DMAC7.html)
CN (1) CN110167558A (cg-RX-API-DMAC7.html)
AU (1) AU2017380583A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019012709A2 (cg-RX-API-DMAC7.html)
CA (1) CA3046289A1 (cg-RX-API-DMAC7.html)
IL (1) IL267086A (cg-RX-API-DMAC7.html)
MX (1) MX2019007606A (cg-RX-API-DMAC7.html)
RU (1) RU2019120431A (cg-RX-API-DMAC7.html)
WO (1) WO2018115891A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11352332B2 (en) 2018-02-26 2022-06-07 AlzeCure Pharma AB Triazine derivatives for treating diseases relating to neurotrophins
GB201810668D0 (en) 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
GB201912404D0 (en) * 2019-08-29 2019-10-16 AlzeCure Pharma AB New compounds
CN113057957A (zh) * 2021-03-30 2021-07-02 福建中医药大学 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途
CN113893334A (zh) * 2021-10-19 2022-01-07 内蒙古医科大学第二附属医院 基于cAMP/PKA-CREB-BDNF信号通路的七氟烷影响抑制剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2718799A1 (de) * 1977-04-27 1978-11-09 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer
CA2765030C (en) * 2009-06-09 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
WO2011070177A2 (en) * 2009-12-11 2011-06-16 Baltic Technology Development, Ltd. Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators

Also Published As

Publication number Publication date
MX2019007606A (es) 2020-07-29
WO2018115891A1 (en) 2018-06-28
RU2019120431A (ru) 2021-01-22
IL267086A (en) 2019-08-29
RU2019120431A3 (cg-RX-API-DMAC7.html) 2021-03-09
AU2017380583A1 (en) 2019-06-27
US20200113910A1 (en) 2020-04-16
CA3046289A1 (en) 2018-06-28
CN110167558A (zh) 2019-08-23
BR112019012709A2 (pt) 2019-11-26
JP2020502225A (ja) 2020-01-23
EP3558320A1 (en) 2019-10-30

Similar Documents

Publication Publication Date Title
JP7636796B2 (ja) 脳障害を治療するためのn-置換インドール及び他の複素環化合物
US12209071B2 (en) Triazine derivatives for treating diseases relating to neurotrophins
US20200113910A1 (en) Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases
JP7808226B2 (ja) 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法
CN106488907B (zh) O-烷基-苯亚甲基胍衍生物及其治疗与错误折叠蛋白质累积有关疾病的治疗用途
CN112513032B (zh) 作为trk受体的调节剂的4-取代的苯基-1,3,5-三嗪衍生物
KR102962516B1 (ko) 뉴로트로핀에 관련된 질환의 치료를 위한 트리아진 유도체
JP6831376B2 (ja) トリアゾール誘導体
US8314092B2 (en) Substituted [(5H-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists
TW202423910A (zh) 化合物
KR20210028649A (ko) Trk 수용체의 조절제로서의 4-치환된 페닐-1,3,5-트리아진 유도체
RU2816837C2 (ru) Производные триазина для лечения заболеваний, связанных с нейротрофинами
HK40033844A (en) Triazine derivatives for treating diseases relating to neurotrophins
HK40033844B (en) Triazine derivatives for treating diseases relating to neurotrophins

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190627

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201221

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220919

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20221128

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220919

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I